The dynamics of leukocyte-platelet adhesion and plateletplatelet interaction in whole blood are not well understood. Using different platelet agonists, we have studied the whole blood kinetics of these heterotypic and homotypic interactions, the relative abilities of different leukocyte subsets t o participate in platelet adhesion, and the ligands responsible for adhesion. When platelet aggregation was inhibited by the Arg-Gly-Asp-Ser (RGDS) peptide, thrombin stimulation of whole blood resulted in platelet expression of granule membrane protein 140 (GMP-140) and, simultaneously, a marked increase in the percentage of monocytes and neutrophils (PMN) binding platelets, as well as an increase in the number of platelets bound per monocyte and PMN. Lymphocytes were unaffected. Monocytes bound more platelets and at an initially faster rate than PMN. This increase in monocyte and PMN adhesion t o platelets was completely inhibited by the blocking monoclonal antibody (MoAb), G1, t o GMP-140. When the combination of epinephrine and adenosine diphosphate (epi1ADP) was used as a less potent agonist in the presence of RGDS, GMP-140 expression per platelet was less, and while monocyte-platelet conjugates formed, PMN-T HAS BEEN previously demonstrated that thrombin-I activated platelets adhere to isolated fractions of monocytes and neutrophils (PMN).' This adhesion is mediated primarily through expression of platelet activation dependent granule external membrane/granule membrane protein 140 (PADGEM/GMP-140),2,3 also designated CD62, on the platelet surface. Using a newly designed sensitive assay, we have also demonstrated that even "unactivated" platelets (not expressing GMP-140) are capable of binding to isolated monocyte and PMN fractions at relatively low numbers of platelets per le~kocyte.~ However, the dynamics and interaction of homotypic (platelet-platelet) and heterotypic (leukocyte-platelet) adhesion in whole blood are not well understood. In addition, the relative affinities of competing leukocyte subsets (monocytes, PMN, and lymphocytes) for adhesion to platelets in whole blood is not defined. Such investigations can clarify the normal physiology of adhesion between inflammatory and hemostatic cells and allow future studies of both the functional significance 
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of blood cell adhesion and the possible alterations in adhesion that may occur in pathologic states.
MATERIALS AND METHODS
Antibodies. All monoclonal antibodies (MoAbs) were used as purified whole IgG, or IgM, except for the anti-GMP-140 MoAb designated "Gl," which was used both whole and as an Fab, fragment. All experiments included irrelevant isotype-specific mouse MoAbs as negative controls. The MoAbs 1E3' and G1' (the latter kindly donated by Dr R. McEver, University of Oklahoma, Oklahoma City) are both specific for GMP-l40/PADGEM, but only G1 inhibits adhesion of stimulated platelets to neutrophils and monocytes. SZ26 and P2' (AMAC, Inc, Westbrook, ME) recognize GPIb and GPIIb/IIIa, respectively. Anti-CD45 (HLE; BectonDickinson Immunocytometry Systems, San Jose, CA) recognizes a CD45 isoform present on PMN, monocytes, and lymphocytes but neither erythroid cells nor platelets? The MoAb MMA (Leu-M1, Becton-Dickinson) recognizes CD15. 9 Blood was drawn from normal human volunteers into a final concentration of sodium citrate, 0.38%. To prevent clotting through fibrinogen-GPIIb/IIIa binding, blood was then incubated with Arg-Gly-Asp-Ser (RGDS)'" peptide (Peninsula Laboratories, Inc, Belmont, CA) at a final concentration of 1 mg/mL. The sample was stimulated (time 0) with diluent or bovine thrombin (Sigma, St Louis, MO) at a final concentration of 0.1 U/mL at 37°C. The blood was kept at 37°C for the entire assay. Preliminary studies demonstrated no differences between samples that were agitated or stationary during the assay. For blocking studies with MoAbs, G1 Fab,, 1E3, or isotypematched control MoAb were preincubated with whole blood for 5 minutes before the addition of agonist. The concentrations of MoAbs used were found to be saturable at 1 KglmL.
Epinephrine-adenosine diphosphate (epi/ADP) stimulation of whole blood. Blood was drawn into porcine heparin at a final concentration of 14 U/mL or citrate as described previously. In some experiments, RGDS was added at a final concentration of 1 mg/mL. One milliliter of blood was then incubated at 37°C with diluent or epinephrine HCI (Parke-Davis, Morris Plains, NJ) at a final concentration of 1 Kmol/L for 10 minutes, followed by diluent or ADP (Sigma) at a final concentration of 5 pmol/L at 37°C.
Thrombin stimulation of whole blood.
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Addition of ADP was designated as time 0. Blood samples were kept at 37°C throughout the experiment. Studies performed at 22°C demonstrated similar results. MoAb blocking experiments were performed as above.
Sample preparation. At each sampling time point, 100 pL of blood was removed and incubated with paraformaldehyde (final concentration 1%) for 60 minutes, followed by addition of 1/8:vol/ vol Tris-glycine solution (250 mmol/L Tris and 500 mmol/L glycine), as described previously? Preliminary experiments using isolated cell fractions demonstrated that paraformaldehyde h ation did not significantly change the percentages of leukocytes binding platelets. After 15 minutes, samples were washed three times in Tyrodes-HEPES (TH) buffer" (HEPES 5 mmol/L, NaCl 140 mmol/L, KC12.7 mmol/L, dextrose 5.5 mmol/L, NaH,PO, 0.42 mmol/L, and NaHCO, 12 mmol/L, pH 7.4). Samples were then resuspended in 200 pL of TH buffer. Each sample was divided in half, one part for fluorescent labeling of leukocyte-platelet conjugates and the other half for labeling of platelets for GMP-140 and measurement of platelet aggregates.
For determination of the percentage of platelets expressing GMP-140 and the percentage of platelet aggregates, 100 pL of sample was incubated with fluorescein isothiocyanate (F1TC)-anti-GPIb (SZ2; AMAC) or FITC-antiGPIIb/IIIa (P2; M A C ) and biotinylated anti-GMP-140 (1E3) MoAbs for 20 minutes, then washed and resuspended in 100 pL TH buffer. The sample was then incubated with saturating concentrations of phycoerythrin (PE)-avidin (Becton-Dickinson) for 20 minutes, washed, and resuspended in 300 pL TH buffer for fluorescence-activated cell sorter (FACS) analysis. 12 For leukocyte-platelet conjugate analysis, 100 pL of sample was incubated with saturating concentrations of FITC-conjugated anti-CD45 and biotinylated anti-GPIb or anti-GPIIb/IIIa MoAbs for 20 minutes, then washed and resuspended in 100 pL TH buffer. PE-avidin labeling and preparation for FACS analysis was performed as described previously.
Samples were analyzed on a FACScan flow cytometer (Becton-Dickinson) with data stored in list mode files. The determination of the percentage of platelets expressing GMP-140 and the percentage of platelet aggregates was performed as previously de~cribed.'~"
The determination of leukocyte-platelet conjugates was per- Citrated whole blood was incubated with RGDS peptide at a final concentration of 1 mg/mL to prevent formation of platelet-platelet aggregates. After addition of diluent or thrombin (0.1 U/mL at time 0), samples were studied at various time points (Fig 1) first 6 minutes for the percentage of leukocytes binding thrombin-activated platelets was 14.l%/min for monocytes, S.l%/min for PMN, and 0.7%/min for lymphocytes, indicating that monocytes initially bound platelets at nearly three times the rate compared with PMN-platelet conjugate formation.
In addition to the percentages of monocytes and PMN with bound platelets after thrombin stimulation, Fig 1A  also shows the simultaneous percentages of circulating we measured surface CD15 fluorescence on leukocyte subsets in this whole blood system. Thrombin stimulation had no effect on the surface density of leukocyte CD15, as measured by its mean fluorescence, shown in Table 2 . For In Fig 3, the mean platelet fluorescence per bound leukocyte was measured for the same experiment as Fig 1. This fluorescence corresponds in a relative fashion to the number of platelets bound to each leukocyte. Thrombin stimulation (Fig 3A) leukocytes in the control sample (diluent stimulation only, Fig 3B) did not change over time.
epilADP stimulation of whole blood with RGDS peptide. Formation of platelet aggregates was again inhibited by preincubating heparinized whole blood with RGDS (1 mgImL). The sample was incubated with epi for 10 minutes, followed by ADP stimulation at time 0 (Fig 4) . Over the next 30 minutes, the percentage of monocytes with adherent platelets more than doubled (30% to 72%, Fig  4A) , and the number of platelets bound per monocyte (as estimated by fluorescence in Fig 4B) also increased (200 to 850). However, unlike after thrombin, PMN-platelet conjugate formation did not increase either with respect to the percentage of cells binding platelets (21% to 24%, Fig 4A) or the number of platelets bound per cell (relative fluorescence 440 to 450, Fig 4B) . Lymphocytes were again unafFor personal use only. on October 24, 2017. by guest www.bloodjournal.org From fected. Although thrombin and epi/ADP resulted in similar percentages (72% v 69%) of free platelets expressing GMP-140 (Table 3) , thrombin stimulation resulted in a fourfold higher surface expression of GMP-140 per platelet, as measured by fluorescence, when compared with the weaker agonist epi/ADP. Experiments performed using citrated whole blood yielded similar results.
epi/ADP stimulation of whole blood without RGDS peptide. Figure 5 illustrates a representative study in which heparinized whole blood (without RGDS) at 37°C was incubated with 1 kmol/L epi followed by 5 ymol/L ADP at time 0 (Fig  5A) or no agonist (Fig 5B) . RGDS peptide was not used to allow the formation of platelet-platelet aggregates. Because the combination of epi and ADP is a less potent platelet agonist than thrombin and there is little fibrin formation with epi/ADP, platelet-platelet interaction is reversible, and whole blood clotting does not occur despite the absence of RGDS. Figure 5A demonstrates the percentage of leukocytes with bound platelets over time after epi/ADP. The percentage of all leukocytes with bound platelets decreased markedly after ADP. The percentage of monocytes with adherent platelets subsequently increased over time, reaching a peak similar to that seen in Fig 4A. However, the percentage of PMN and lymphocytes with adherent platelets increased only slightly and did not fully recover to the preagonist level of binding. Figure 5B demonstrates that, in the absence of agonist, leukocyteplatelet binding changes minimally over the time of the assay, similar to Fig 1B. Experiments in which citrate was substituted for heparin as the anticoagulant and then stimulated with epi/ADP showed an identical pattern of leukocyte-platelet adhesion.
To further study this dynamic pattern of leukocyteplatelet adhesion after the addition of epi/ADP in a situation where platelet aggregate formation occurs, we simultaneously measured the percentages of (1) free (not bound to leukocytes) GMP-140-positive platelets; (2) free platelet aggregates; and (3) leukocytes with bound platelets over time (Fig 6) . In this experiment, 1 pmol/L epi was added to citrated whole blood 10 minutes before 5 p.mol/L of ADP was added at time 0. Figure 6A demonstrates a slight decrease and a later increase in leukocyte-platelet binding after epi, and then a rapid decrease (like the experiment in Fig 5A) Figure 6B demonstrates that immediately after ADP, the percentages of both free platelet aggregates and GMP-140-positive platelets increased dramatically. Furthermore, the peak percentages of platelet aggregates and GMP-140-positive platelets corresponded to the nadir of leukocyte-platelet binding. After this point, the percentage of free platelet aggregates and GMP-140-positive platelets then decreased as the simultaneous percentage of monocytes (and to a lesser extent PMN) with bound platelets increased.
In a separate experiment (Fig 7A) , the inhibition of the recovery of leukocyte-platelet adhesion after epi/ADP was examined by preincubating whole blood (without RGDS) with the G1 MoAb to GMP-140 before stimulation with epi and ADP. In the presence of the G1-blocking MoAb, the preagonist binding of leukocytes to platelets was unaffected. There was also no change in the immediate decrease in leukocyte-platelet adhesion after ADP. However, the recovery phase for leukocyte-platelet conjugates after the initial decrease in binding was nearly completely abolished. There was only a slight increase in the percentage of monocytes with adherent platelets, but this remained well below the preagonist levels. Platelet aggregate formation and dissociation was identical to that shown in Fig 6B, indicating that the G1 MoAb only blocked the GMP-140-dependent recovery of leukocyte-platelet adhesion and had no effect on platelet aggregates. In Fig 7B, 
DISCUSSION
Leukocyte-platelet adhesion is likely of physiologic importance not only for the targeting of both cell types to appropriate inflammatory and/or hemostatic sites but also for functional alterations in these cells. For example, metabolic cooperation between platelets and heterotypic blood cells has been postulated. Studies have demonstrated that platelets supply free cholesterol to monocytes for cholesteryl ester ~ynthesis'~; such monocytes may then participate in foam cell generation seen in atherosclerotic lesions.16 Platelets have also been shown to provide prostaglandin endoperoxide H, to endothelial cells and lymphocytes for production of prostacyclin (PGI,), which is a potent vasodilator and platelet inhibit~r.",'~ Recent work has demonstrated that platelets synthesize leukotriene C, (LTC,) from PMN-derived L T h ; this cell-cell interaction for eicosanoid synthesis is aspirin-insensitive and independent of platelet acti~ation.'~ To further understand these interactions, model systems are necessary in which heterotypic and homotypic conjugate formation can occur together under circumstances similar to those found in vivo. For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Isolated PMN and monocytes have been shown to bind activated and, to a lesser degree, unactivated platelet fractions. The kinetics of this adhesion and some responsible receptor-ligand pairs have been determined in However, the interactions between platelets and leukocytes have not previously been examined in whole blood. The current studies have determined the conditions under which heterotypic cell-platelet adhesion occurs in whole blood, the dynamic interaction between homotypic (plateletplatelet) and heterotypic (leukocyte-platelet) adhesion in whole blood, and the relative affinities of different leukocyte subsets for activated (GMP-140-positive) platelets.
Baseline studies demonstrated that unstimulated whole blood samples show both a minority of leukocytes with bound platelets and a low level of platelets bound per white blood cell. These results were similar to those observed when unstimulated isolated cell fractions were allowed to recombine in vitro; this included a similar percentage of both neutrophils and peripheral blood lymphocytes that bound resting platelets. However, monocytes in whole blood had a lower percentage of platelet binding (45%) compared with isolated cell fractions (87%) in which monocytes and platelets are recombined in the absence of red blood cells, plasma, and other leukocytes. In the whole blood assay, the presence and much higher concentration of other leukocytes that bind unactivated platelets, albeit less effectively than monocytes, would be expected to decrease monocyte-platelet adhesion when compared with the isolated fraction assay. It is also interesting to note that, in whole blood, RGDS peptide reduced the percentages of all leukocytes with adherent unactivated platelets by more than 50%, whereas in isolated cell fraction experiments, RGDS had no effect on unactivated platelet binding to leukocytes. One important difference between isolated cell fraction studies and these whole blood experiments is the lack of plasma fibrinogen in the former. Because RGDS inhibits fibrinogen binding to the GPIIb/IIIa integrin receptor," it is possible that fibrinogen-integrin interaction plays a role in unactivated platelet adhesion to leukocytes in whole blood. When isolated cell fractions are studied, only platelet and leukocyte-associated fibrinogen is available for such an interaction and thus the effect of added RGDS in isolated fractions is minimal. It is also possible that RGDS may lower the baseline percentage of leukocyte-platelet binding through inhibition of platelet-platelet interaction. If platelet-platelet conjugates are present on the leukocyte surface at baseline, their aggregate platelet marker fluorescence will determine the lower limits of detection of platelet binding, especially since there may be some fluorescent quenching by adjacent erythrocytes in this whole blood assay, If RGDS dissociates these platelet conjugates on the cell surface, then the aggregate fluorescence is decreased, lowering the measured percentage of leukocyte binding.
When platelets were stimulated with thrombin in whole blood under conditions that preclude formation of platelet aggregates (RGDS)? our studies have shown that: (1) platelets rapidly express GMP-140; ( 2 ) monocytes rapidly bind platelets and continue to increase their cumulative platelet binding as the number of available circulating activated platelets decreases; (3) PMN bind platelets at about one third the rate of monocytes and in far fewer numbers of platelets per PMN; (4) lymphocyte-platelet adhesion is not changed by thrombin; and (5) all of the increased monocyte and PMN adhesion of platelets after thrombin is dependent on the epitope of platelet GMP-140, which is recognized by the G1 MoAb but not the epitope recognized by 1E3. These findings are consistent with data reported in isolated fraction experiments2a4 and present further evidence for a competitive advantage of monocytes over PMN in both the initial binding of GMP-140-positive platelets and the cumulative binding of platelets, ie, the eventual number of platelets bound per leukocyte. This advantage of monocytes over PMN is particularly striking in view of the log-higher concentration of PMN in whole blood. The advantage of monocytes over PMN is further supported by the increase in monocyte-platelet conjugate formation observed after epi/ADP with no increase for PMN-platelet adhesion. This competitive advantage of monocytes over PMN for platelet conjugate formation may be exaggerated when platelets are stimulated to express relatively less surface GMP-140 per platelet compared with the expression of this receptor on platelets after thrombin stimulation ( Table 3) .
The advantage of monocytes over PMN in binding activated platelets cannot be currently explained by data regarding the postulated receptor on PMN and monocytes for binding GMP-140. The identity of this receptor is controversial. Larsen et all4 have found evidence that CD15; a nonsialated penta-sugar not present on resting lymphocytes, is a leukocyte ligand for PADGEM/GMP-140. However, other investigators have not found conclusive evidence that CD15 is the GMP-140 receptor and have additionally shown that the leukocyte receptor for GMP-140 is likely a sialated glycoprotein, unlike CD15.22,23 Our studies suggest a competitive advantage of monocytes over PMN for adhesion to activated platelets, an intriguing finding in this regard because there is a 30-fold higher expression of CD15 per PMN compared with monocytes. Our data suggest either that CD15 is not the receptor for GMP-140-positive platelets or that qualitative differences between monocyte and PMN CD15 exist with respect to GMP-140 binding (a less likely alternative in view of the small size of the CD15 sugar).
To determine the competitive dynamics of plateletplatelet versus leukocyte-platelet adhesion in whole blood, epi/ADP in the absence of RGDS was used to cause reversible platelet aggregati~n.'~ Our studies demonstrated that: (1) initial platelet activation resulted in preferential platelet-platelet adhesion with a simultaneous decrease in the percentage of all leukocytes with bound platelets; ( 2 ) as the platelet aggregates spontaneously dissociated, the activated platelets returned to heterotypic cell adhesion over time; (3) monocytes again had the advantage over PMN for this recovery of platelet adhesion; and (4) the G1 (blocking) MoAb, but not the 1E3 (nonblocking) MoAb, to GMP-140 prevented the recovery of leukocyte-platelet adhesion at a time when platelet aggregates were dissociating. These studies suggest that early after the addition of agonist, adherent platelets dissociate from monocytes, PMN, and lymphocytes to undergo homotypic binding (aggregation)
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From mediated by an RGDS binding site revealed by the agonist. As platelet aggregates dissociate, the GMP-140-positive platelets readhere to monocytes and to a lesser degree to PMN, but not to lymphocytes. This is consistent with studies demonstrating that resting lymphocytes do not bind GMP-140 or activated platelets?* It is important to note that the setting in which the dynamics of leukocyte-platelet adhesion are determined in this study differs from in vivo conditions by several factors. Because these experiments were performed under relatively static conditions, the crucial effects of blood flow and shear rate are not taken into account when cell-cell interactions are measured. In addition, perturbations introduced by endothelial injuq or inflammation are not accounted for in this study and may significantly affect the interactions between blood cells described. It will be instructive for future studies to determine similar leukocyte-platelet and homotypic platelet interactions under more physiologic conditions.
As noted earlier, metabolic cooperation has been shown to occur between platelets and heterotypic blood cells; presumably these interactions require some ability for these cells to adhere or at least remain in close proximity for a time?5s26 These whole blood studies have demonstrated that monocytes have a competitive advantage over PMN for binding to activated platelets and that platelet-platelet adhesion is initially favored over platelet-leukocyte adhesion after addition of a platelet agonist. Subsequent platelet aggregate dissociation allows GMP-14kxpressing platelets to readhere to monocytes and, to a lesser extent, to PMN. The functional consequences of such adhesion are not yet known, but the dynamics of interaction between hemostatic and inflammatory cells provide a basis for studying relevant pathophysiologies.
